Diplomat to distribute new primary hyperkalemic, hypokalemic periodic paralysis treatment

Diplomat Pharmacy, Inc. announced on Thursday it will be the sole distributor of KEVEYIS (dichlorphenamide), recently approved for the treatment of primary hyperkalemic and hypokalemic periodic paralysis, a group of rare hereditary disorders that cause episodes of muscle weakness or paralysis.

"We are excited to be a sole distributor of KEVEYIS and give patients a therapy option for primary hyperkalemic and hypokalemic periodic paralysis," Gary Kadlec, president of Diplomat, said. "The FDA approval of KEVEYIS is an important advancement in the treatment of hyperkalemic and hypokalemic periodic paralysis, and we are proud to be able to support these patients and their caregivers."

KEVEYIS is the first medicine approved by the Food and Drug Administration for the treatment of primary periodic paralysis, estimated to affect around 5,000 people in the United States.

Taro has created the Keys2Care program, which will provide a group of patient support services to ensure people diagnosed with periodic paralysis can receive treatment with KEVEYIS as soon as possible. Diplomat is working with Taro to offer access and support to patients who are prescribed KEVEYIS and their caregivers as part of this program.

KEVEYIS is expected to be available in the third quarter of this year. To be notified when KEVEYIS is available, enroll at www.keveyis.com.